Upregulation of Mad2 facilitates in vivo and in vitro osteosarcoma progression

Oncology Reports

Volumn 28, Issue 6, 2012, Pages 2170-2176

  Yu, Ling ^a   Liu, Shiqing ^a   Guo, Weichun ^a   Zhang, Bo ^a   Liang, Yi ^b   Feng, Qisheng ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cancer stem cell; Invasiveness; Mad2; Metastasis; Osteosarcoma

Indexed keywords

DOXORUBICIN; METHOTREXATE; PROTEIN MAD2;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD DYSCRASIA; CANCER GROWTH; CANCER INVASION; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CELL ACTIVITY; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, SURFACE; BONE NEOPLASMS; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS C-KIT; REPRESSOR PROTEINS; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 84868146265     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2032     Document Type: Conference Paper

References (23)

1. Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115:1531-1543, 2009.
2. Savage SA and Mirabello L: Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma 2011:548151, 2011.
3. Ottaviani G and Jaffe N: The etiology of osteosarcoma. Cancer Treat Res 152:15-32, 2009.
4. Pritchard DJ, Finkel MP and Reilly CA Jr: The etiology of osteosarcoma. A review of current considerations. Clin Orthop Relat Res: 14-22, 1975.
5. Dobles M and Sorger PK: Mitotic checkpoints, genetic instability, and cancer. Cold Spring Harb Symp Quant Biol 65:361-368, 2000. (Pubitemid 32611958)
6. Silva P, Barbosa J, Nascimento AV, Faria J, Reis R and Bousbaa H: Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint. Cell Prolif 44:391-400, 2011.
7. Weaver BA and Cleveland DW: Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell 8:7-12, 2005. (Pubitemid 40991810)
8. Sotillo R, Hernando E, Diaz-Rodriguez E, et al: Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 11:9-23, 2007. (Pubitemid 46054519)
9. Eytan E, Braunstein I, Ganoth D, et al: Two different mitotic checkpoint inhibitors of the anaphase-promoting complex/cyclosome antagonize the action of the activator Cdc20. Proc Natl Acad Sci USA 105:9181-9185, 2008.
10. Yu L, Guo WC, Zhao SH, Tang J and Chen JL: Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma. APMIS 118:222-229, 2010.
11. Hisaoka M, Matsuyama A and Hashimoto H: Aberrant MAD2 expression in soft-tissue sarcoma. Pathol Int 58:329-333, 2008. (Pubitemid 351677533)
12. Tanaka K, Nishioka J, Kato K, et al: Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers. Jpn J Cancer Res 92:952-958, 2001. (Pubitemid 32970436)
13. Wang L, Yin F, Du Y, et al: MAD2 as a key component of mitotic checkpoint: A probable prognostic factor for gastric cancer. Am J Clin Pathol 131:793-801, 2009.
14. Darling AJ, Boose JA and Spaltro J: Virus assay methods: accuracy and validation. Biologicals 26:105-110, 1998. (Pubitemid 28502290)
15. Gibbs CP, Kukekov VG, Reith JD, et al: Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7:967-976, 2005.
16. Kato T, Daigo Y, Aragaki M, et al: Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients. Lung Cancer 74:124-131, 2011.
17. Sotillo R, Schvartzman JM, Socci ND and Benezra R: Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature 464:436-440, 2010.
18. Adhikari AS, Agarwal N, Wood BM, et al: CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 70:4602-4612, 2010.
19. Duesberg P: Does aneuploidy or mutation start cancer? Science 307:41, 2005.
20. Duesberg P, Fabarius A and Hehlmann R: Aneuploidy, the primary cause of the multilateral genomic instability of neoplastic and preneoplastic cells. IUBMB Life 56:65-81, 2004. (Pubitemid 38418923)
21. Bachoo RM, Maher EA, Ligon KL, et al: Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269-277, 2002. (Pubitemid 41039151)
22. Ilyas M, Straub J, Tomlinson IP and Bodmer WF: Genetic pathways in colorectal and other cancers. Eur J Cancer 35:335-351, 1999. (Pubitemid 29151929)
23. Liang Y, Zhong Z, Huang Y, et al: Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. J Biol Chem 285:4931-4940, 2010.